GOLDMAN SACHS GROUP INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$164,140
+317.7%
164,584
+519.8%
0.00%
Q1 2024$39,300
-3.7%
26,554
-29.1%
0.00%
Q4 2023$40,817
+15.7%
37,447
+25.3%
0.00%
Q3 2023$35,270
-5.7%
29,890
+12.7%
0.00%
Q2 2023$37,393
-91.1%
26,520
-90.5%
0.00%
Q1 2023$419,654
+2447.7%
279,769
+1887.1%
0.00%
Q4 2022$16,472
+96794.1%
14,079
-9.0%
0.00%
Q3 2022$17
-86.6%
15,473
-80.7%
0.00%
Q2 2022$127
-99.9%
80,169
-37.1%
0.00%
Q1 2022$196,000
-19.0%
127,432
+29.2%
0.00%
Q4 2021$242,000
-1.2%
98,659
+1.6%
0.00%
Q3 2021$245,000
+544.7%
97,071
+625.8%
0.00%
Q2 2021$38,000
-91.9%
13,374
-93.3%
0.00%
Q1 2021$467,000
+344.8%
198,638
+64.3%
0.00%
Q2 2020$105,000
+94.4%
120,899
+84.0%
0.00%
Q1 2020$54,000
-38.6%
65,710
-33.5%
0.00%
Q4 2019$88,000
+100.0%
98,833
+119.1%
0.00%
Q3 2019$44,00045,1120.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders